PUBLICATION HIGHLIGHTS EASE OF USE AND SUPERIOR PERFORMANCE OF PARSORTIX SYSTEM IN HARVESTING CTCs FROM METASTATIC BREAST CANCER PATIENTS Quantity, purity and quality of CTCs captured using the ...
NuCana plc has initiated an expansion study of its anti-cancer drug NUC-7738 combined with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, with initial data expected in Q4 2025 ...
GUILDFORD, SURREY / ACCESS Newswire / July 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research ...
GUILFORD, SURREY AND PLYMOUTH MEETING, PA / ACCESS Newswire / November 5, 2025 / CELLBXHEALTH plc (AIM:CLBX)(OTCQX:ANPCY), a global leader in circulating tumour cell (CTC) intelligence, announces the ...
Haleon PLC (GB:HLN) announced an update on their ongoing clinical study. Haleon PLC (GB:HLN) is conducting a decentralised, real-world study titled “A Decentralised, Open-labelled, Clinical Study to ...
Development of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay successfully completed for AstraZeneca Results of Eisai Phase 2 pilot study supports the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results